Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

ERT) with Cerezyme(R) (imiglucerase) to the pharmacological chaperone Plicera(TM). Thirty patients were enrolled in this trial, which was designed to demonstrate safety and to evaluate various doses and dose regimens of Plicera. The study subjects on average were on ERT with Cerezyme(R) for ten years prior to entering this study.

Preliminary data are available for the first twenty study subjects. Key findings include the following:

-- Plicera was generally safe and well-tolerated at all doses evaluated

and no serious adverse events have been reported

-- The level of the enzyme deficient in people with Gaucher disease

(GCase) as measured in white blood cells increased in 15 of the 20

patients

-- In the cohort with the highest Plicera exposure, 5 out of 5 patients

responded to Plicera with, on average, a near tripling of their GCase

levels from baseline

-- The 5 patients without a clear increase in GCase levels from baseline

were in either the lowest dose cohort or the cohort dosed least

frequently

-- 16 of 20 patients in this study had at least one copy of the N370S

mutation, the most common mutation known to cause Type 1 Gaucher

disease.

"As the Gaucher program at Amicus advances, it has increasing significance and value for our company. Plicera has the potential to address the needs of the vast majority of people living with Gaucher disease and may offer a new standard of care in the treatment and maintenance of their disease. We expect to move forward aggressively in 2008 with additional studies as we explore the full potential of switching Gaucher patients from Cerezyme(R) to Plicera," said John F. Crowley, Amicus President & CEO.

Amicus expects that the results for all thirty patients enrolled in the first Plicera Phase 2 study to be presented at the ACMG meeting in March.

Pompe Disease:

During the fourth quarte
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
(Date:8/27/2014)... , Aug. 27, 2014 ... the "Global Lactic Acid  (Biodegradable Polymer, Food ... Trends & Forecasts to 2019" report to ... simplest hydroxyl-carboxylic acid with an asymmetrical carbon atom. ... the biodegradable polymer, food and beverage, personal care ...
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, the ... today announced the hiring of veteran equity analyst Charles ... analyst. Mr. Butler will focus on the biotech/biopharma sector. ... a wealth of experience and a broad network of ... Senior Managing Director and Head of Equities at Guggenheim ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014 is ... of the global isotope ratio mass spectrometer industry. ... industry including definitions, classifications, applications and industry chain structure. ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... researchers at Arizona State University, have been awarded funding ... producing renewable fuel. This award will permit four ... Jones in the department of chemistry and biochemistry, to ... This will lead to ways of significantly increasing the ...
... 2011 Spherix Incorporated (Nasdaq: SPEX ) ... metabolic syndrome and atherosclerosis and provider of technical and ... companies – today reported financial results for the year ... Upcoming Highlights Pharmaceutical Development ...
... 30, 2011 SuperNova Diagnostics®, Inc., a privately-held ... applications, announced today that it has signed an ... Ltd. ("KSB"), a biotechnology diagnostics company specializing in ... and research reagents in China and affiliated markets ...
Cached Biology Technology:Biological nanowires expedite future fuel production 2Spherix Announces 2010 Financial Results 2Spherix Announces 2010 Financial Results 3Spherix Announces 2010 Financial Results 4Spherix Announces 2010 Financial Results 5Spherix Announces 2010 Financial Results 6Spherix Announces 2010 Financial Results 7SuperNova Diagnostics® Announces Agreement with KSB Diagnostics of China to Commercialise Neopterin Diagnostics 2SuperNova Diagnostics® Announces Agreement with KSB Diagnostics of China to Commercialise Neopterin Diagnostics 3
(Date:8/27/2014)... Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... sold in the offering consists of 2,000 shares of ...
(Date:8/27/2014)... Duke University researchers have identified a gene that could ... encodes a protein in the cell membrane of plants ... plant,s water conservation machinery accordingly. , "It,s similar ... of biology at Duke. , The findings, which ... could make it easier to feed the world,s growing ...
(Date:8/27/2014)... the brain of mice, scientists have altered the ... by Howard Hughes Medical Institute investigator Susumu Tonegawa ... that the connections between the part of the ... and the part of the brain that stores ... , Altering those connections can transform a ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Water 'thermostat' could help engineer drought-resistant crops 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4
... health authorities all over the world are expecting a ... chronic diseases of bone, muscle and joints. The IOF-ESCEO ... become an important educational and research forum to help ... diseases. Held annually in Europe, the Congress is ...
... cells exist in two different states and each state ... an international collaboration of researchers. Their finding sheds new ... disease. "The lethal part of cancer is its ... senior study author Max S. Wicha, M.D., Distinguished Professor ...
... project launches today, investigating the social and political drivers ... largest carbon dioxide emitter by volume, rather than focusing ... change worldwide we need to transform the way we ... population. And nowhere is the approach to innovation across ...
Cached Biology News:New breast cancer stem cell findings explain how cancer spreads 2
... Product Goat polyclonal to Cholesterol ... Reactivity / Specificity Cross-reacts with ... Background Information Cholesterol oxidases exist ... oxidases and are implicated in bacterial pathogenesis. ...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Biology Products: